ClinicalTrialsFinder

CLDN18.2 Positive Clinical Trials in Beijing, Beijing Municipality

1 recruitingBeijing, Beijing Municipality, China

Showing 1–1 of 1 trials

Recruiting
Phase 2

IBI343 in Combination With Sintilimab and SOX Regimen for Perioperative Treatment of Resectable, Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Gastroesophageal Junction AdenocarcinomaCLDN18.2 PositivePrimary Gastric Adenocarcinoma
Innovent Biologics (Suzhou) Co. Ltd.90 enrolled1 locationNCT07483567